JP2023052559A - Bead beating tubes and methods for extracting deoxyribonucleic acid and/or ribonucleic acid from microorganisms - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide improved methods for bead beating and bead beating systems useful therefor.

SOLUTION: Disclosed is a method for lysing cells contained in a blood sample comprising: agitating blood or a sample obtained by treating, extracting or separating the blood, in the absence of lysis buffer, in a bead beating system that comprises (i) a sample tube or a blood collecting tube and (ii) beads.

SELECTED DRAWING: None

COPYRIGHT: (C)2023,JPO&INPIT

Description

1. BACKGROUND Genetic testing and diagnosis of infectious diseases play an important role in the field of clinical microbiology. To overcome the inherent biases and limitations of culture-based methodologies, genetic tests are increasingly being used to detect microorganisms in samples. In order to be able to carry out such genetic tests, it is necessary to lyse the cells in order to be able to extract DNA and/or RNA from the microorganism in the highest possible concentration.

Zhongtang Yu et al., 2004, "Improved extraction of PCR-quality community DNA from digesta and fecal samples", BioTechniques, Vol. 36(5):808-812 describe methods for isolating DNA from gut contents and fecal samples. In that method, 0.25 g of a sample fluid taken from the bovine gastrointestinal system presumed to contain microorganisms, ie bacteria, was first diluted with 500 mM sodium chloride, 50 mM Tris-HCl (pH 8.0), Mixed with 1 mL of buffer containing 50 mM ethylenediaminetetraacetic acid and 4% sodium dodecyl sulfate. Additionally, 0.4 g of sterile zirconia beads are introduced into the sample fluid. The mixture thus obtained is subsequently shaken in the sample tube for 3 minutes by a Mini-Bead Beater ^™ so that the beads break the cell walls of the microorganisms. In this process, the DNA contained within the cell is released. Said buffer also serves to protect the DNA from degradation by DNases contained in the sample fluid. After performing bead crushing, impurities are removed from the sample by precipitation with ammonium acetate. Nucleic acids are obtained by precipitation with isopropanol. In a further method step, the DNA is digested sequentially with RNase and proteinase K and subsequently purified by column.

The method has the drawback that it is relatively complicated. As the sample fluid is diluted by the addition of buffer, the concentration of DNA in the sample is reduced. Therefore, the method allows only limited detection accuracy and sensitivity.

Thus, there is a need for improved apparatus and methods for lysing cells and extracting nucleic acids from microorganisms contained in sample fluids.

2. SUMMARY The present disclosure relates to improved bead breaking tubes, as well as bead breaking systems and methods. The terms "bead crushing tube" and "sample tube" are used interchangeably herein. Without wishing to be bound by theory, the inventors believe that bead disruption allows nucleic acids to dissolve into solution. The present disclosure provides, in part, that the use of bead disruption in nucleic acid extraction methods results in loss of nucleic acid due to absorption to the beads, and that such loss blocks the binding sites on the beads in an appropriate amount. It is based on the finding that it can be hindered by blocking agents. The present disclosure also suggests that although some lysis buffers that have been used to date in bead disruption may contain reagents that act as blocking agents, such reagents are used in significantly lower amounts than commonly used. based on the recognition that it can be used in As used herein, the term "lysis buffer" refers to a buffer solution used to disrupt open cells. A lysis buffer can include, for example, a buffer (eg Tris-HCl) and one or more salts (eg NaCl, KCl) and/or detergents (eg sodium dodecyl sulfate).

Furthermore, the present disclosure also recognizes that some biological samples, such as blood, inherently contain blocking agents, so that bead disruption can be performed in the absence of additives such as lysis buffers. Based on Thus, for example, blood may be collected into a commercially available blood collection tube and then directly subjected to bead disruption by, for example, adding bead breaking beads to the collection tube and agitating the collection tube. Examples of commercially available collection tubes include lavender top tubes with EDTA, light blue top tubes with sodium citrate, gray top tubes with potassium oxalate, or green top tubes with heparin. Alternatively, a portion of the blood may be transferred to a sample tube for bead disruption.

In certain aspects, the present disclosure provides samples for bead disruption that do not inherently contain blocking agents, or bead disruptions that contain blocking agents in amounts below the appropriate amount for effective blocking of nucleic acid absorption by the beads. To provide a system for bead disruption suitable for use with samples of various sizes. The bead breaking system of the present disclosure includes a dry blocking agent. Surprisingly, when the system for bead disruption of the present disclosure is used for lysis of microorganisms and extraction of deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) from microorganisms contained in liquid samples, blocking It has been found that a greater extraction rate of DNA and/or RNA can be achieved than when using corresponding bead crushing tubes containing no agent.

The system for bead disruption of the present disclosure can also avoid the need to combine the sample and lysing solution prior to bead disruption, thus allowing recovery of a greater amount of nucleic acid without sample dilution.

In yet another aspect, the present disclosure provides a method of bead disruption to lyse cells and extract nucleic acids from a biological sample. The method includes performing bead disruption on a biological sample in the absence of a lysis buffer. The bead-breaking method can utilize the bead-breaking system of the present disclosure or a standard bead-breaking system. When using a standard bead breaking system, in some embodiments, one or more blocking agents are added to the bead breaking system. In other embodiments, no blocking agents are added prior to bead disruption, particularly if the biological sample naturally contains one or more blocking agents.

In certain embodiments, the system for bead disruption of the present disclosure includes a container member having an internal cavity, an opening for filling the internal cavity with a sample fluid containing microorganisms, and a device for closing the opening. a sample tube with an attached or non-attached closure, wherein a plurality of macroscopic particles are disposed within the internal cavity, the particles being filled with a sample fluid into the internal cavity to form beads; A disruption tube is adapted to mechanically disrupt cell walls of microorganisms contained in the sample fluid when subjected to mechanical vibration. Exemplary bead breaking systems are described in Section 4.1 and numbered embodiments 1-24 and 90-98 below. Exemplary sample tubes that can be used in the bead disruption system are described in Section 4.1.1 and exemplary blocking agents that can be used in the bead disruption system are described in Section 4 .1.2 and exemplary beads that can be used in the bead breaking system are described in Section 4.1.3.

The present disclosure further provides a method of lysing a microorganism and extracting deoxyribonucleic acid (DNA) and/or ribonucleic acid (RNA) from the microorganism, comprising: providing a sample fluid suspected of containing the microorganism; A plurality of relatively mobile particles are introduced into the sample fluid, and the sample fluid containing the particles is capable of mechanically disrupting the cell walls of microorganisms in which the particles are contained in the sample fluid. It relates to a method of vibrating to be. Exemplary samples from which DNA can be extracted are described in Section 4.2, and exemplary sample pretreatment steps that can be used to prepare the sample prior to nucleic acid extraction are described in Section 4.3. It is Exemplary methods for extracting nucleic acids from a sample, such as a sample described in Section 4.2 or a sample pretreated as described in Section 4.3, are described in Section 4.4 and numbered below. described in embodiments 25-81 and 99-104. Kits useful for carrying out the nucleic acid extraction methods of the present disclosure are described in Section 4.7 and numbered embodiments 82-89 below.

3. Brief description of the drawing

FIG. 1 is a side view of an exemplary bead breaking system (1) including a sample tube (2) and a closure cap (6). Figure 2 is a plan view of the system for bead breaking shown in Figure 1; 2 is a bottom view of the system for breaking beads shown in FIG. 1; FIG. Figure 2 is a longitudinal section through the center plane of the system for bead breaking shown in Figure 1, with the closure cap removed from the sample tube and the internal cavity (3) of the sample tube accessible through the opening (4); One thing is clear. Beads (7) and lyophilized blocking agent (8) are shown in the inner cavity. Figure 2 is a longitudinal section through the center plane of the system for bead breaking shown in Figure 1 filled with sample fluid (5); C. after bead crushing. Intensity of PCR amplification products using DNA recovered from Albicans as template. Calbi144 and Calbi54 are two different C. albicans target gene and HCO1-Rat87 is a negative control gene. This study demonstrated that urea has a blocking effect on bead breakage and that C.I. albicans DNA facilitation. C. after bead crushing. Intensity of PCR amplification products using DNA recovered from Albicans as template. Calbi144 and Calbi54 are two different C. albicans target gene and HCO1-Rat87 is a negative control gene. This study demonstrated that RNA has a blocking effect on bead disruption and C. elegans from PD fluids. albicans DNA facilitation. C. after bead crushing. Intensity of PCR amplification products using DNA recovered from Albicans as template. Calbi144 and Calbi54 are two different C. albicans target gene and HCO1-Rat87 is a negative control gene. C.I. corresponding to the maximum theoretical yield of the extraction. A quantity of C. albicans DNA was included as template. This study was carried out by C.I. albicans DNA can be recovered by bead disruption of blood in the absence of additives. After crushing the beads, the S. Shown is the intensity of PCR amplification products using DNA recovered from Aureus as template. The genes investigated include Eubacteria (Eub), Gram-negative bacteria (Gng), Gram-positive bacteria (Gpo), Staphylococci (AllStaph), Enterobacteriaceae (Entb), S. For detection of Aureus (Sau), Mycoplasma (Myco). N03 Rat 87 is the negative control and CC is the internal control. The S.E.C. corresponding to the maximum theoretical yield of the extraction. Amounts of Aureus DNA were included as template. This study was published by S. Aureus DNA can be recovered by bead disruption of blood in the absence of additives. E. after bead crushing. FIG. 3 shows the intensity of PCR amplification products using DNA recovered from E. coli as template. The genes investigated include Eubacteria (Eub), Gram-negative bacteria (Gng), Gram-positive bacteria (Gpo), E. For detection of coli (Eco), Staphylococcus (AllStaph), Enterobacteriaceae (Entb). N03 Rat 87 is the negative control and CC is the internal control. E.C. corresponding to the maximum theoretical yield of the extraction. A quantity of E. coli DNA was included as template. This study was carried out by E. E. coli DNA can be recovered by bead disruption of blood in the absence of additives.

4. DETAILED DESCRIPTION Bead disruption is a homogenization process used to lyse cells to release their nucleic acid (DNA and RNA) containing contents. The sample is placed in a tube with suitable grinding beads and subjected to high energy mixing. The sample is then typically centrifuged and the lysate collected on top of the beads. Generally, samples subjected to bead disruption are treated with a lysis buffer to facilitate the release of DNA from cells.

The present disclosure relates to improved bead crushing methods and systems for bead crushing. The bead disruption method can be performed without the use of lysis buffers, simplifying the process of cell lysis and nucleic acid extraction, and avoiding sample dilution or minimizing losses due to absorption onto the beads. becomes.

The methods of the present disclosure relate to performing bead crushing using a suitable amount of blocking agent. Blocking agents may be exogenous or endogenous to the sample. For example, urine contains urea, a reagent that has been found to block the binding of nucleic acids in a biological sample to bead crushing beads. Thus, although the present disclosure provides methods for bead disruption of such samples without the addition of exogenous blocking agents, supplementing endogenous blocking agents with exogenous blocking agents is also contemplated. For biological samples that contain no endogenous blocking agent or only a small amount of said blocking agent, an exogenous blocking agent can be used. The present disclosure further provides a system for bead disruption into which a dry blocking agent is introduced, which allows for bead disruption of biological samples without the addition of reagents that result in sample dilution.

Accordingly, the present disclosure provides a system for breaking beads that includes a dry blocking agent. The present disclosure further provides methods of bead disruption to lyse cells in a biological sample and extract nucleic acids from the biological sample. The method includes performing bead disruption on a biological sample in the absence of a lysis buffer. The bead-breaking method can utilize the bead-breaking system of the present disclosure or a standard bead-breaking system. When using a standard bead breaking system, in some embodiments, one or more blocking agents are added to the bead breaking system. In other embodiments, no blocking agents are added prior to bead disruption, particularly if the biological sample naturally contains one or more blocking agents.

Kits containing (or suitable for obtaining) the system for bead disruption of the disclosure are also provided herein.

4.1 Bead Breaking System The present disclosure provides a bead breaking system useful for cell lysis and extraction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from cells (e.g., microorganisms) contained in liquid samples. I will provide a. A system for bead disruption of the present disclosure includes a sample tube and beads and dry blocking agent located within the sample tube. Blocking agents that can be used in the bead breaking system of the present disclosure include urea, guanidine salts, detergents, nucleotides, polyvinylpyrrolidone (PVP) and oligonucleotides. Blocking agents are described in detail in Section 4.1.2. Beads that can be used in the bead crushing system of the present disclosure include beads containing minerals and/or metals. Beads suitable for use in the bead crushing system of the present disclosure are described in Section 4.1.3.

4.1.1 Sample Tube The bead breaking system of the present disclosure includes a sample tube having an internal cavity accessible by an opening and capable of containing beads, blocking agent, and liquid sample. The sample tube may be made of any biologically inert material (e.g. plastic or borosilicate), preferably plastic (e.g. polypropylene, polypropylene copolymer, or polycarbonate). . As used herein, the term "tube" includes vials (eg, crushed vials) and tubes (eg, conical tubes).

The bead breaking system may include a closure for sealing the sample tube over the opening. The closure can be fixed to the sample tube (eg, a cap that is hingedly secured to the sample tube) or can be separable from the sample tube (ie, a removable cap). The sample tube may include a threaded region adapted to mate with a threaded cap. Threads may be on the inner or outer surface of the sample tube (eg, as shown in FIGS. 4-5).

Sample tubes that can be used in the system for bead disruption of the present disclosure are commercially available, eg, screw-cap polypropylene tubes or microtubes. Standard tube sizes such as 0.5 mL, 1.7 mL, 2 mL, 4.5 mL, 7 mL, 15 mL, 50 mL or 250 mL can be used to make the bead breaking tubes and bead breaking systems of the present disclosure. can.

4.1.2 Blocking Agent The bead breaking system of the present disclosure includes a dry blocking agent. As used herein, a "dry" or "dried" blocking agent is a blocking agent that contains less than 20% moisture. In some embodiments, the dry blocking agent is less than 15%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% Contains moisture.

The dry blocking agent is preferably long-term stable, i.e. the bead breaking system can be safely transported and stored for longer periods of time without significantly reducing the blocking effectiveness of the blocking agent. . The dried blocking agent may be loosely disposed in the interior cavity of the container member and/or a portion of or the entire interior cavity of the sample may be coated with a layer or coating of blocking agent. The blocking agent is preferably lyophilized. The blocking agent may be lyophilized before or after adding the beads to the tube.

Examples of blocking agents include one or more chaotropic agents (e.g. urea, guanidine salts), one or more surfactants, one or more nucleotides, polyvinylpyrrolidone (PVP), one or more oligonucleotides, or any combination thereof. Details of such exemplary blocking agents are provided below in Sections 4.1.2.1-4.1.2.5. Including a blocking agent (e.g., a surfactant) that contributes to the lysis of the microbial cell wall can improve the yield of nucleic acids prepared using the system for bead disruption of the present disclosure, and the sample prior to bead disruption. and the lysing solution can be avoided. Generally, the amount of blocking agent used in the bead breaking system of the present disclosure is less than that used in the lysing solution.

A bead-breaking system can be manufactured by freeze-drying a lysis solution (also called extraction buffer or lysis buffer) in a bead-breaking tube. Lysis solutions containing blocking agents are known in the art or can be purchased commercially.

In some embodiments, the blocking agent comprises one or more chaotropic agents. In some embodiments, the blocking agent comprises one or more surfactants. In some embodiments, the blocking agent comprises one or more nucleotides. In some embodiments, the blocking agent comprises one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents and one or more surfactants. In some embodiments, the blocking agent comprises one or more chaotropic agents and one or more nucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more surfactants and one or more nucleotides. In some embodiments, the blocking agent comprises one or more surfactants and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more nucleotides and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents, one or more surfactants, and one or more nucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents, one or more surfactants, and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents, one or more nucleotides, and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more surfactants, one or more nucleotides, and one or more oligonucleotides. In some embodiments, the blocking agent comprises one or more chaotropic agents, one or more detergents, one or more nucleotides, and one or more oligonucleotides.

The blocking agent may comprise or further comprise ethylenediaminetetraacetic acid (EDTA) and/or its sodium salt. EDTA binds calcium, magnesium and iron and thus deactivates deoxyribonucleases and ribonucleases. This measure prevents degradation of DNA and RNA contained in sample fluids processed using the system for bead disruption. Thus, higher detection sensitivity and higher reproducibility of measurement results are possible during the investigation of DNA and/or RNA extracted from cells (eg, microorganisms) using the system for bead disruption of the present disclosure.

The blocking agent may be loosely disposed, for example in powdered form, in the internal cavity of the container member. The powder may for example be mixed with the beads in the sample or placed in the sample tube as a layer on top and/or under the beads. Alternatively or additionally, the inner wall of the sample tube may be at least partially coated with a layer or coating of blocking agent. The layer or coating can be produced by evaporating the liquid from an aqueous mixture containing the blocking agent added to the sample tube. In another embodiment, some or all of the beads in the bead breaking system may be coated with a blocking agent.

4.1.2.1 Chaotropic Agents Chaotropic agents disrupt the structure of macromolecules such as proteins and nucleic acids and denature the macromolecules. Chaotropic solutes reduce the net hydrophobic effect of hydrophobic regions due to disordering of water molecules in close proximity to proteins. This solubilizes the hydrophobic regions in solution, thereby denaturing the protein. This is also true for hydrophobic regions in lipid bilayers. When a critical concentration of chaotropic solutes is reached (in the hydrophobic region of the bilayer) membrane integrity will be compromised and cells will lyse.

Exemplary chaotropic agents that can be used as blocking agents are shown below.

Urea: When the blocking agent comprises urea (or thiourea; as used herein, the term urea includes thiourea unless otherwise specified in the context), the amount of urea is , the amount of sample fluid intended to be used in the system for bead crushing and the concentration of urea dissolved in the sample fluid after addition to the sample tube of 10 grams/liter to 100 grams/liter. between 50 grams/liter and 100 grams/liter, between 20 grams/liter and 50 grams/liter, or between 25 grams/liter and 35 grams/liter. Thus, for the above-described embodiment, if 1 mL of sample is to be added to a 2 mL tube, the amount of urea used in the blocking agent is between 10 mg and 100 mg, between 50 mg and 100 mg, respectively. Between 20 mg and 50 mg, or between 25 mg and 35 mg, and where 0.8 mL of sample is to be added to a 2 mL tube, the amount of urea used in the blocking agent is between 8 mg and 80 mg, respectively. , between 40 and 80 mg, between 16 and 40 mg, or between 20 and 28 mg.

Salts: Certain salts can act as chaotropic agents. Salts can have chaotropic properties by shielding charges and preventing stabilization of salt bridges. Chaotropic salts include various salts of guanidine, lithium and magnesium.

Guanidine Salts: Guanidine salts that can be used as blocking agents in the bead crushing system of the present disclosure include guanidine isocyanate, guanidine chloride, and combinations thereof.

Lithium Salts: Lithium salts that can be used as blocking agents in the bead crushing system of the present disclosure include lithium perchlorate, lithium acetate, and combinations thereof.

Magnesium Salts: Magnesium salts that can be used as blocking agents in the bead crushing system of the present disclosure include magnesium chloride.

Detergents: Certain detergents, such as sodium dodecyl sulfate (“SDS”), can act as chaotropic agents. The use of surfactants as blocking agents is described in Section 4.1.2.3.

4.1.2.2 Creatinine When the blocking agent contains creatinine, the presence of creatinine in the internal cavity of the sample tube is an indication of DNA and/or RNA contained in samples processed using the system for bead disruption. can interfere with the decomposition of Additionally, creatinine prevents non-specific binding of DNA and/or RNA to the inner walls of the beads and/or sample tube. This allows for higher yields when extracting DNA and/or RNA from treated cells (eg, microorganisms) using a bead crushing tube system.

4.1.2.3 Surfactants Surfactants that can be used as blocking agents in the bead crushing system of the present disclosure include sodium dodecyl sulfate, sodium lauroylsulfate sarcosinate, polyoxyethylene (20) Sorbitan monolaurate, and combinations thereof. Polyoxyethylene (20) sorbitan monolaurate is also known as polysorbate 20.

The amount of surfactant used in the blocking agent can be matched with the amount of sample fluid intended to be used in the bead breaking system. In certain embodiments, the concentration of surfactant dissolved in the sample fluid after adding the sample fluid to the sample tube is between 1 mg/mL and 50 mg/mL, between 1 mg/mL and 25 mg/mL, or between 25 mg/mL and 25 mg/mL. /mL to 50 mg/mL. Thus, for the above-described embodiment, if 1 mL of sample is to be added to a 2 mL tube, the amount of surfactant used in the blocking agent is 1 mg to 50 mg, 1 mg to 25 mg, respectively. or range from 25 mg to 50 mg, and 0.8 mL of sample is to be added to a 2 mL tube. It will range from 8 mg to 20 mg, or from 20 mg to 40 mg.

4.1.2.4 Nucleotides Nucleotides that can be used in the bead disruption system of the present disclosure include ribonucleotides, deoxyribonucleotides, and combinations thereof.

The nucleotides may be naturally occurring. Naturally occurring ribonucleotides are adenosine monophosphate, guanosine monophosphate, cytosine monophosphate, and thymidine monophosphate. Naturally occurring deoxyribonucleotides that can be used as blocking agents are deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxycytosine monophosphate, and deoxythymidine monophosphate.

The nucleotides may be non-naturally occurring analogues of naturally occurring nucleotides. Examples of non-naturally occurring analogs include, but are not limited to, peptide nucleotides, locked nucleic acid ("LNA") nucleotides (containing bicyclic sugar moieties in place of deoxyribose or ribose sugars), Nucleotides with uncharged bridges (e.g., methylphosphonates, phosphotriesters, amidophosphites, carbamates, etc.) and charged bridges (e.g., thiophosphates, dithiophosphates, etc.), and pendant moieties Nucleotides containing are included. In specific embodiments, the analogs are 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl)uracil, 5-fluorouracil, 5 -bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, dihydrouracil, inosine, N6-isopentenyl adenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5 -Methoxyaminomethyl-2-thiouracil, β-D-mannosylkeosine, 5′-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyl adenine, uracil-5-oxyacetic acid methyl ester, uracil -5-oxyacetic acid, oxybutoxin, pseudouracil, chaosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-methyl oxyacetate uracil-5-oxyacetic acid, pseudouracil, chaosine, 2-thiocytosine, and 2,6-diaminopurine, or 7-deazaguanosine.

In some embodiments, the blocking agent comprises a mixture of at least 2, at least 3, or 4 naturally occurring ribonucleotides. In other embodiments, the blocking agent comprises a mixture of at least 2, at least 3, or 4 naturally occurring deoxyribonucleotides. In still other embodiments, the blocking agent comprises a mixture of at least 2, at least 3, 4 or even more than 4 nucleotide analogues. In still other embodiments, the blocking agent comprises (a) a mixture of naturally occurring ribonucleotides and naturally occurring deoxyribonucleotides, (b) a mixture of naturally occurring ribonucleotides and nucleotide analogs. , (c) a mixture of naturally occurring deoxyribonucleotides and nucleotide analogues, or (d) a mixture of naturally occurring ribonucleotides, naturally occurring deoxyribonucleotides and nucleotide analogues.

The amount of ribonucleotides used in the blocking agent can be matched with the amount of sample fluid intended to be used in the bead disruption system. In certain embodiments, the concentration of ribonucleotides dissolved in the sample fluid after adding the sample fluid to the sample tube is 200 pg/ml to 20 μg/mL, 1 ng/ml to 15 μg/ml, or 1 μg /ml to 10 μg/ml. Thus, for the above-described embodiment, if 1 mL of sample is to be added to a 2 mL tube, the amounts of ribonucleotides used in the blocking agent are 200 pg-20 μg, 1 ng-15 μg, respectively. Or range from 1 μg to 10 μg, and if 0.8 mL of sample is to be added to a 2 mL tube, the amount of ribonucleotides used in the blocking agent is from 0.8 ng to 160 pg to 16 μg, respectively. 12 μg, or in the range of 0.8 μg to 8 μg.

4.1.2.5 Oligonucleotides Oligonucleotides useful as blocking agents can be synthesized or produced from naturally occurring sources.

"Oligonucleotide" as referred to herein does not refer to the size of the molecule, but refers to a polymeric form of nucleotides of any length. Generally, however, the oligomer will be no more than 2000 nucleotides, no more than 1000 nucleotides, more usually no more than 500 nucleotides, even more usually no more than 250 nucleotides. The term oligonucleotide includes double- and single-stranded DNA and RNA (but preferably is at least partially single-stranded). It also includes known types of modifications such as labels, methylations, "caps" and analogs known in the art (e.g. analogs described in Section 4.1.2.4). One or more substitutions of naturally occurring nucleotides are included.

The oligonucleotides may be mixtures of various sizes and/or ribonucleotides, deoxyribonucleotides, nucleotide analogs, or combinations of two or more of the foregoing (e.g., ribonucleotides and deoxyribonucleotides). mixtures, mixtures of ribonucleotides and nucleotide analogues, mixtures of deoxyribonucleotides and nucleotide analogues, or mixtures of ribonucleotides, deoxyribonucleotides and nucleotide analogues). In some embodiments, the blocking agent comprises RNA.

Synthetic oligonucleotides that can be used in the bead disruption system of the present disclosure are generally 2-120 nucleotides in length. In various embodiments, the oligonucleotides are 2, 5, 8, 10, 15, 18, 25, 40, 50, 80, 100 or 120 nucleotides in length, or any set of the above values. lengths ranging between, such as 2-100 nucleotides in length, 2-50 nucleotides in length, 2-25 nucleotides in length, 5-40 nucleotides in length, 2-15 nucleotides in length, 8-120 nucleotides in length, 8-80 nucleotides in length, Oligonucleotides having a length of 10-100 nucleotides, 15-50 nucleotides, 50-100 nucleotides, 100-120 nucleotides, and the like.

Naturally occurring oligonucleotides can be prepared by fragmenting DNA from one or more naturally occurring sources such as salmon sperm DNA, calf thymus DNA, herring sperm DNA, or combinations thereof.

The amount of oligonucleotides used in the blocking agent can be matched with the amount of sample fluid intended to be used in the bead disruption system. In certain embodiments, the concentration of oligonucleotides dissolved in the sample fluid after adding the sample fluid to the sample tube is 200 pg/ml to 20 μg/mL, 1 ng/ml to 15 μg/ml, or 1 μg /ml to 10 μg/ml. Thus, for the above-described embodiment, if 1 mL of sample is to be added to a 2 mL tube, the amounts of oligonucleotides used in the blocking agent are 200 pg-20 μg, 1 ng-15 μg, respectively. Or range from 1 μg to 10 μg, and if 0.8 mL of sample is to be added to a 2 mL tube, the amount of ribonucleotides used in the blocking agent is from 0.8 ng to 160 pg to 16 μg, respectively. 12 μg, or in the range of 0.8 μg to 8 μg.

4.1.3 Beads The system for bead disruption of the present disclosure includes beads that are movable relative to each other when placed in a sample fluid. As used herein, the term "bead" includes both spherical and non-spherical particles. The beads include mineral beads such as crystalline particles such as zirconium, zircon (zirconium silicate) and zirconia (zirconium dioxide), quartz, aluminum oxide, silicon carbide (also known as carborundum), garnets, ceramic particles, Beads may be made of glass (eg silicon dioxide glass or silica) or combinations comprising one or more of the above (eg zirconia/silica beads or zirconia/yttrium beads). The beads may be metal beads, such as stainless steel beads or chrome steel beads.

For recovery of bacterial DNA, the beads preferably contain quartz particles and/or zirconium particles. Such beads are commercially available in large quantities and are chemically inert to DNA and RNA. The quartz and/or zirconium particles have a relatively high specific gravity and can be hard and have sharp edges. They are therefore very suitable for opening cell membranes when subjected to mechanical vibrations.

The bead material and size for a given bead crushing system can be selected by one skilled in the art depending on the identity of the cell type in the fluid sample to be processed. Generally, the beads will range in diameter from 50 μm to 3 mm. For the extraction of nucleic acids from bacterial cells, small to medium size beads, typically made of glass or zirconium, with diameters ranging from 50 μm to 0.5 mm can be used. For the extraction of nucleic acids from larger microbial cells such as yeast, medium-sized or large beads (e.g., glass or zirconium with a diameter of 0.5 mm, 1 mm, or 1.5 mm) are commonly made. beads) can be used. Beads of various sizes and compositions for treating various cell types are commercially available. For example, www. denville scientific. com/sites/default/files/Bead_Blasting_Notes. See Benchmark Scientific, Product Note: Benchmark Bead Beating Guide, available in pdf.

The system for bead disruption of the present disclosure provides multiple types of beads and/or multiple sizes of the same type, especially when it is desired to recover nucleic acids from multiple sources (e.g., bacterial and fungal DNA). May contain beads. Examples of bead breaking systems with multiple types of beads include a combination of aluminum oxide and silicon carbide beads, a combination of ceramic and silica beads, a combination of glass and zirconium oxide beads, a combination of zirconia and aluminum oxide beads. Combinations, or systems with a combination of silicon carbide beads and glass beads are included. These various types of beads may be of the same size or of different sizes.

4.2 Samples Examples of samples from which nucleic acids can be extracted using the bead disruption methods of the present disclosure include various fluid samples. In some cases, the sample may be a bodily fluid sample from the subject. A sample can include tissue taken from a subject. A sample can include bodily fluids, secretions, and/or tissues of a subject. The sample may be a biological sample. The biological sample may be a bodily fluid sample, a secretion sample and/or a tissue sample. Examples of biological samples include, but are not limited to, blood, serum, saliva, urine, gastric and digestive juices, tears, feces, semen, vaginal fluid, interstitial fluid from tumor tissue, ocular fluid. , sweat, mucus, earwax, oil, glandular secretions, breath, cerebrospinal fluid, hair, nails, skin cells, plasma, nasal swab or nasopharyngeal wash, cerebrospinal fluid, cerebrospinal fluid, tissue, throat swab, wound swab, raw placental fluid, amniotic fluid, umbilical cord blood, lymphatic fluid, body cavity fluid, sputum, pus or other wound exudate, infected tissue sampled by debridement or excision, cerebrospinal fluid, lavage, leukopoiesis, peritoneal dialysate , milk and/or other excreta, and plants and their parts.

The sample may be placed in the bead crushing tube as-taken from the subject, or may be pretreated in some form (e.g., as described in Section 4.3 below) prior to placement in the bead crushing tube. ), stored, or transported. The sample can be added to the bead breaking system without intervention or a lot of time.

A subject can provide a sample and/or a sample can be collected from a subject (eg, a blood sample can be collected in a blood collection tube containing an anticoagulant, such as EDTA). A subject may be a human or non-human animal. Samples can be collected from living or deceased subjects. The animal may be a mammal, such as a farm animal (eg, cow, pig, sheep), a sport animal (eg, horse) or a pet (eg, dog or cat). A subject may be a patient, a clinical subject, or a preclinical subject. The subject may be undergoing diagnosis, treatment, and/or disease management or lifestyle care or preventative care. The subject may or may not be under the care of a health care professional.

In some embodiments, the sample may be an environmental sample. Examples of environmental samples can include air samples, water samples (eg, groundwater, surface water, or wastewater), soil samples, or plant samples.

Additional samples may include foodstuffs, beverages, manufacturing materials, textiles, chemicals, therapeutic agents or any other sample.

4.3 Sample Pretreatment In some cases, it may be advantageous to pretreat the sample prior to processing in the system for bead disruption of the present disclosure. Examples of pretreatment steps that may be used prior to placing the sample in the bead crushing tube include filtration, distillation, extraction, concentration, as described herein or otherwise known in the art. Includes centrifugation, inactivation of interfering components, addition of reagents, and the like.

To maximize the recovery of DNA from the cell type of interest, it is particularly advantageous to remove unwanted cell types and particulate matter from the biological sample prior to placing it in the bead disruption tube of the present disclosure. It appears to be.

When it is intended to detect bacteria in a biological sample, the biological sample is pretreated through a filter to retain particulate matter and non-microbial cells while the bacterial cells (if desired) are retained on the filter. spores) should be allowed to pass through. As used herein, a "filter" is a membrane or device that allows differential passage of particles and molecules based on their size. Generally, this is accomplished by having the pores in the filter of a certain standard size. For example, filters of particular interest for bacterial detection applications have pores that are large enough to allow the passage of bacteria, but small enough to prevent the passage of eukaryotic cells present in the sample of interest. have Generally, bacterial cells range in diameter from 0.2 μm to 2 μm (micrometers or microns), most fungal cells range in diameter from 1 μm to 10 μm, and platelets are approximately 3 μm in diameter. There are, and most nucleated mammalian cells are generally 10 μm to 200 μm in diameter. Filter pore sizes of less than 2 μm or less than 1 μm are therefore particularly suitable for removing non-bacterial cells from microbiological samples when the detection of bacteria is intended.

In addition to, or instead of, a filtration step, the microbiological sample can be centrifuged to remove cells and debris from the sample prior to bead disruption. Centrifugation parameters that sediment eukaryotes but not bacterial cells are known in the art. The supernatant can then be filtered if desired.

The filtrate produced by the filtration step may be a "sample" and may be placed in a bead crushing tube according to the present disclosure or subjected to further pretreatment steps (eg, concentration or dilution).

4.4 Bead Breaking As an initial step in nucleic acid preparation, the sample is placed in a bead breaking tube for bead breaking. The bead breaking process can utilize the bead breaking system of the present disclosure or a standard bead breaking system. In some cases, one or more exogenous blocking agents can be added when using standard bead disruption systems, whereas biological samples containing endogenous blocking agents , the addition of exogenous blocking agents is not required. If one or more blocking agents are added, they can be added to the bead breaking tube before sample addition, after sample addition, or both sample and one or more blocking agents can be added simultaneously. (For example, the sample and one or more blocking agents may be mixed and then transferred to a bead crushing tube).

After the sample is placed in the bead crushing tube, the tube is agitated to mechanically lyse the cells. Lysis can be accomplished with a normal laboratory vortexer or homogenizer. Processing times in a vortex apparatus are 3 to 10 times longer than in professional homogenizers, but vortexing easily disrupts cells and is inexpensive.

Many homogenizers suitable for bead crushing are commercially available and can be used with the bead crushing system of the present disclosure. Exemplary homogenizers are the BeadBug and BeadBlaster 24 (Benchmark Scientific), PowerLyzer 24 (MO Bio Laboratories Inc.), FastPrep-24, FastPrep-24 5G and SuperFastPrep-1 (MP Biomedicals), and 16 (BioSpec Products).

Homogenization parameters may be selected according to the manufacturer's recommendations. Generally, the time for mechanical disruption (eg, bead disruption) is less than 1 second, 1 second to 5 seconds, 5 seconds to 10 seconds, 10 seconds to 25 seconds, 25 seconds to 60 seconds, 1 minute to 2 minutes, 2 minutes to 5 minutes, may be 5 minutes or longer. The number of repetitions of mechanical disruption (eg, number of bead breaking operations) may be 2, 3, 4, 5, 6, 7, 7-10, 10 or more repetitions. you can The speed of breakage (e.g. speed or setting of bead breakage) is less than 50 revolutions per minute, 50-100 revolutions, 100-250 revolutions, 250-500 revolutions, 500-750 revolutions, 750-1000 revolutions per minute. revolutions, 1000 to 1500 revolutions, 1500 to 2000 revolutions, 2000 revolutions or more revolutions (oscillations).

4.5 Nucleic Acid Purification After cell lysis, the fluid sample is separated from the beads, eg, by pipetting or otherwise removing the liquid sample from the sample tube, leaving the beads settling to the bottom of the sample tube.

Impurities that may interfere with analysis of the extracted DNA may be removed by precipitation of the impurities by known methods, such as using ammonium acetate, or using commercially available kits.

Nucleic acids can be recovered, washed, and optionally further purified. Recovery and/or purification of nucleic acids can be performed using conventional methods, eg, by precipitation with isopropanol, or using commercially available kits or automated instruments.

4.6 Nucleic Acid Analysis Analysis of a sample for the presence of nucleic acids of interest (e.g., bacterial or fungal DNA) can be performed by any nucleic acid analysis method, such as, but not limited to, the polymerase chain reaction (PCR). , isothermal amplification, reverse transcription-polymerase chain reaction (RT-PCR), quantitative real-time polymerase chain reaction (Q-PCR), digital PCR, gel electrophoresis, capillary electrophoresis, mass spectrometry, fluorescence detection, ultraviolet spectrometry, high Bridization assay, DNA or RNA sequencing, restriction analysis, reverse transcription, NASBA, allele-specific polymerase chain reaction, polymerase cycling assembly (PCA), asymmetric polymerase chain reaction, post-exponential linear polymerase chain reaction (LATE-PCR), helicase dependent amplification (HDA), hot-start polymerase chain reaction, sequence-specific polymerase chain reaction (ISSR), inverse polymerase chain reaction, ligation-mediated polymerase chain reaction, methylation-specific polymerase chain reaction (MSP), multiplex polymerase chain reaction, nested polymerase chain reaction, solid-phase polymerase chain reaction, or any combination thereof. Such techniques are well known to those skilled in the art. Knowing the sequence of the target nucleic acid allows the scientist to construct primers and/or probes that allow amplification and/or detection of the target. PCR amplicons may also be sequenced to confirm their identity.

A system for bead disruption according to the present disclosure extracts DNA and/or RNA from microorganisms contained in a sample fluid in concentrations sufficient for direct microbiological interrogation of DNA and/or RNA in a manner known per se. It is possible to extract This can be done in particular by contacting the sample fluid with receptors immobilized on the surface that specifically bind to DNA and/or RNA and/or DNA and/or RNA components contained therein. can. The binding of DNA and/or RNA and/or DNA and/or RNA components to the receptor is detected and optionally quantified in a manner known per se by markers, in particular optical markers, e.g. fluorochromes. can be done. Alternatively, DNA and/or RNA from microorganisms contained in the sample fluid can be amplified, for example by PCR, prior to testing.

4.7 Kits The present disclosure further provides kits containing (or suitable for obtaining) the systems for bead disruption of the present disclosure. The kit comprises a sample tube, such as a sample tube described in Section 4.1.1, one or more blocking agents, such as those described in Section 4.1.2, and/or one or more beads. , for example, the beads described in Section 4.1.3. Each of the one or more blocking agents may be pre-lyophilized and contained within the tube or separately from the tube. Likewise, the beads may be contained within the tube or separate from the tube.

In some embodiments, the kit includes sample tubes and one or more blocking agents. In further embodiments, the kit further comprises one or more types of beads.

Kits of the present disclosure may include one or more components for sample pretreatment, such as saline, one or more buffer solutions, filters as described in Section 4.3, and the like.

The kit may contain one or more pathogens of interest (e.g., Mycobacterium tuberculosis, Mycobacterium avium subsp. paratuberculosis, Staphylococcus aureus). ), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae, Haemophilus parainfluenzae (Haemophilus parainfuluezae), Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter sp., Bordetella pertussis ( Bordetella pertussis, Neisseria meningitidis, Bacillus anthracis, Nocardia sp., Actinomyces sp., Mycoplasma pneumoniae, Chlamydia Chlamydia pneumonia, Legionella species, Pneumocystis jiroveci, influenza A virus, cytomegalovirus, rhinovirus, Enterococcus faecium, Acinetobacter baumannii), Corynebacterium amycolatum, Enterobacter aerogenes, Enterococcus faecalis CI4413, Serratia marcescens, Streptococcus equi and Candida albicans (one or more of Candida albicans)).

The kit comprises one or more pathogens of interest (e.g., Mycobacterium tuberculosis, Mycobacterium avium subsp. paratuberculosis, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter spp., Bordetella pertussis, Neisseria meningitidis, Bacillus sp. Anthracis, Nocardia spp., Actinomyces spp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp., Pneumocystis jirovecii, Influenza A virus, Cytomegalovirus, Rhinovirus, Enterococcus faecium, Acinetobacter baumannii , Corynebacterium amycolatum, Enterobacter aerogenes, Enterococcus faecalis CI4413, Serratia marcescens, Streptococcus equi and Candida albicans). can contain. In one embodiment, the one or more probes comprise oligonucleotides labeled with a fluorescent dye. Different probes may be labeled with different dyes for simultaneous detection of multiple pathogens of interest.

5. Exemplary Bead Breaking System An exemplary bead breaking system is shown in the drawings. The system for bead breaking, indicated by reference numeral (1) in Figures 1-3, comprises a sample tube (2) having an internal cavity (3) and a closable opening (4). The sample tube is preferably made of plastic, but may be made of other biologically inert materials.

A sample fluid (5), presumed to contain microorganisms, is filled into the internal cavity (3) of the sample tube (2) through the opening (4) and can be removed therefrom. In order to close the opening (4), the sample tube has a closure (6) adapted to be sent to an open position and a closed position, which bounds the opening (4) to the sample tube (2). It is designed as a closure cap including an inner thread adapted to be screwed with an outer thread provided in the edge region of the outer wall of the.

In the inner cavity (3) are further arranged beads (7) (for example 2 grams of silicon dioxide and/or zirconium beads) whose largest dimension is on average about 100 μm. The beads (7) are available in loose bulk form that are movable relative to each other. A freeze-dried blocking agent (8) is also placed in the inner cavity (3).

The beads (7) are contained in the sample fluid (5) when the sample fluid (5) is filled in the internal cavity (3) and the bead breaking tube is subjected to mechanical vibration, for example ultrasonic vibration. It has the function of mechanically destroying the cell walls of microorganisms. These vibrations can be generated with a vibration generator, not illustrated in detail in the drawing, and transmitted to the system for bead breaking (1). Such a vibration generator is commercially available from MP Biomedicals under the name MPBio bead beater. Due to cell wall disruption, the nucleic acids (eg DNA) contained in the microorganisms are released and dissolved in the sample fluid (5).

6. 6. CASE STUDY 6.1 Use of bead disruption to recover pathogen DNA from sputum Mycobacterium tuberculosis (“MTB”) is an obligately pathogenic bacterial species in the family Mycobacteriaceae, responsible for most cases of tuberculosis. It is the causative factor. It is primarily a respiratory pathogen of mammals and it infects the lungs. There is evidence that mycobacteria can enter a state of non-replication or dormancy (sporulation) during stress such as nutrient deprivation or hypoxia. Spore formation makes it difficult to lyse bacterial cells and extract bacterial DNA.

Further complicating recovery of mycobacterial DNA is that mycobacterial strains are commonly isolated from the sputum of infected patients. Sputum is thick, viscous, and difficult to handle. Most sputum specimens for analysis contain varying amounts of organic debris and a wide variety of contaminating, normal or transient flora. Chemical clarification/treatment is commonly used to reduce viscosity and kill contaminants while allowing recovery of mycobacteria.

Samples suspected of containing MTB pose a potential hazard to the user. Therefore, to mitigate this risk, the sputum sample may be pretreated by heating and/or adding reagents suitable for inactivating the microorganisms present in the sample. Microbial inactivation, such as MTB, involves heating for denaturation of active proteins (e.g. 90°C for 5 minutes), enzymatic digestion of cell wall structures, physical disruption of cells or mechanical processes for inactivation of cells. It can be done by physical destruction, chemical treatment, or a combination thereof.

Sputum samples (generally collected in volumes between 1 mL and 10 mL, between 5 mL and 10 mL or more) first reduce their viscosity and heterogeneity to process samples consistently can be liquefied for Sputum samples pose a particular problem. MTB in sputum is one of the most intractable cell and sample types due to the lipid-rich, hydrophobic cell walls of acid-fast bacilli and the viscous, heterogeneous nature of sputum. Standard extraction methods for sputum generally include treatment with mucolytic agents, often N-acetyl-L-cysteine (NALC), zephyran-trisodium phosphate (Z-TSP) or benzalkonium. followed by centrifugation, decantation, and resuspension.

Thus, when processing highly viscous samples, such as sputum, the sample may be subjected to chemical treatment to reduce its viscosity so that one or more subsequent processing steps are not hindered. In one embodiment, liquefaction of sputum samples by chemical treatment with a mucolytic agent is performed at 60° C. for 20 minutes. Sputum has a viscosity ranging from about 100 cP to 6000 cP (mPas) at a shear rate of 90 s ⁻¹ . Viscosity, measured in mPas, is determined by dividing the shear strength by the shear rate. Preferably, liquefying said sample reduces the viscosity of sputum by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.

After resuspension, the sample is added to the bead disruption system of the present disclosure (described in Section 4.1) for cell lysis as described in Section 4.4. After lysis and nucleic acid extraction (see Section 4.5), MTB DNA can be analyzed by PCR amplification of MTB sequences and MTB drug resistance can be analyzed by amplification of the drug resistance gene. The sputum sample may also contain other bacterial and viral pathogens, including but not limited to Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae. , Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter spp., Bordetella pertussis, Neisseria meningitidis, Bacillus anthracis, Nocardia spp., Actinomyces Cess spp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp., Pneumocystis jirovecii, influenza A virus, cytomegalovirus, and rhinovirus can be analyzed.

6.2 Use of Bead Disruption to Recover DNA from Veterinary Pathogens Mycobacterium avium subsp. It is a veterinary pathogen that causes chronic granulomatous gastroenteritis. MAP is transmitted directly in a herd via semen, milk, colostrum and in the uterus, and indirectly via an oral route (fecal-oral route) through contaminated food, feed, pasture, water, and the like. JD has a profound effect on livestock productivity (early culling and reduced milk production) and the livestock industry suffers great economic losses. Efforts to control JD have been hampered by the persistence of MAP in soil and water and by subclinical and clinical bovine hair fall.

As mentioned in the previous section, spore formation makes it difficult to lyse mycobacterial cells and extract bacterial DNA. Accordingly, the system for bead disruption of the present disclosure can be used to improve MAP recovery. For example, the bead crushing system can be used to recover DNA from MAP present in milk, soil, feces, semen, and the like.

Milk samples can be processed directly using the system for bead disruption of the present disclosure, or can be pretreated, for example, to increase the concentration of MAP, if present in the sample. An exemplary pretreatment method includes centrifuging a milk sample to obtain a milk fat fraction, a whey fraction, and a pellet. The milk fat fraction and the pellet can be pooled and added to the bead disruption system of the present disclosure for cell lysis.

Fecal feed can be pretreated, for example, by preparing a fecal suspension, which is then added to the bead crushing system of the present disclosure for cell lysis. Exemplary fecal suspensions are prepared by mixing a fecal sample with water, saline, or a buffer (e.g., sodium phosphate, phosphate-buffered saline, Tris, etc.), allowing the mixture to settle and separate, followed by It can be prepared by centrifuging the supernatant and finally resuspending the pellet in a suitable liquid such as water, saline or buffer.

A soil sample can be suspended in a liquid (eg, water, saline, or buffer) and then added to the bead crushing system of the present disclosure for dissolution. A semen sample can similarly be pretreated by combining the semen sample with a volume of water, saline or buffer prior to bead crushing.

6.3 Use of bead disruption to recover pathogen DNA from wounds For detection of wound infection, wound swabs can be incubated in saline solution, cell culture medium, or sample preparation solutions from commercial kits. . The swab is generally incubated for a period of about 5 minutes to 1 hour, more preferably 0.25 hours to 1 hour (eg 0.25 hours, 0.5 hours or 0.75 hours). Suitable volumes of solution are 200 μL to 10 mL, in particular embodiments 500 μL, 1 mL, 2 mL, 5 mL, 8 mL, or ranges bounded by any two of the above embodiments, such as 1 mL to 5 mL, 500 μl-10 mL, 200 μl-8 mL and so on. The solution can be shaken or agitated periodically to facilitate the release of pathogen cells from the swab. After the incubation period is over, the swab may be squeezed and discarded.

The solution can then be placed into the bead crushing system of the present disclosure. Optionally, the solution is filtered and/or concentrated prior to bead crushing.

Pathogens that commonly infect wounds include, but are not limited to, E. Cori, P. Aeruginosa, E. Faecium, S. aureus (including MRSA), K. Newmonier, A. Baumannii, C. Amicolatum, E. Aerogenes, E. Faecalis CI4413, S. Marcescens, S. Equi and C.I. Contains albicans. Thus, wound swab samples can be analyzed for any of the above organisms, either alone or in combination.

6.4 Use of Bead Fragmentation to Recover Pathogen DNA from Peritoneal Dialysis Fluid Peritoneal dialysis is a treatment for patients with severe chronic kidney disease. This type of dialysis uses the peritoneal membrane of the patient's abdomen as a membrane for exchanging fluids and dissolved substances from the blood. Fluid is introduced through a permanent tube in the abdomen and then drained to cleanse excess salts, uric acid and other waste products. Solutes are exchanged between blood and dialysate by osmosis through the peritoneum. After an appropriate amount of time, the dialysate is removed from the peritoneum and discarded. The blood is thus brought into equilibrium and terminal metabolites, such as uric acid, are prevented from accumulating indefinitely in the blood.

A primary complication of peritoneal dialysis is infection due to the presence of permanent tubes in the abdomen. At least one site of infection is intraperitoneal, resulting in abdominal pain, cloudy dialysate effluent, and pathogen detection on Gram stain or on culture from within the catheter. Additionally, the external surfaces of tissue tunnels or catheters are common sites of infection from contact contamination. Infections in tissue tunnels are most commonly due to introduction through cutaneous sites. Infection can cause peritonitis and in some cases death.

Peritoneal infections can be detected in peritoneal dialysate drawn from individuals undergoing peritoneal dialysis. S. aureus and P. Aeruginosa is responsible for most infections, but other bacteria (Diphtheriae, anaerobes, non-fermentative bacteria, streptococci, non-tuberculous mycobacteria, Legionella, yeasts and fungi) may also be involved. . Thus, peritoneal dialysate samples can be analyzed for any of the above organisms, either alone or in combination.

Peritoneal dialysate may be pretreated by filtration and optionally concentration as described in Section 4.3.

6.5 Use of Bead Fragmentation to Recover DNA from Wastewater Contaminants Implementation of U.S. Pat. No. 9,290,796 for Detection of Problematic Bulking Bacterial Species in Biological Wastewater Treatment Methods Example 1 describes extracting DNA from wastewater collected from a wastewater treatment plant using a bead crushing protocol. The bead-breaking protocol can be adapted to incorporate the bead-breaking system of the present disclosure.

6.6 Use of Bead Disruption to Recover DNA from Food Pathogens Liquid food samples may be pretreated by filtration and/or centrifugation as previously described in Section 4.3 prior to bead disruption. For example, the beverage can be pretreated, preferably by filtration, to recover any microorganisms that may be present. Microorganisms recovered by filtration can optionally be washed and subjected to centrifugation prior to bead disruption. For the detection of pathogens in solid food such as meat or fish, a sample of the food can be swabbed to recover the microorganisms from the surface of the food. The organisms can then be washed off the swab and then subjected to bead disruption.

In some cases, it may be desirable to pre-incubate the food sample for a period of time prior to bead crushing to encourage growth of pathogens (eg Salmonella) that may be present on or in the sample. For example, solid food samples can be ground using a laboratory blender (eg Stomacher® circulator, Seward Limited, UK) and then incubated to encourage microbial growth (eg 8-12 hours). )be able to. A sample of the culture can then be subjected to bead disruption.

6.7 Use of Bead Fragmentation to Recover Pathogen DNA from Blood The development of rapid molecular diagnostic tests for human infections remains the highest priority of the World Health Organization for improving the health of the world's population. (Daar et al., 2002, Nat. Genet. 32:229-232). Severe blood infections are a significant cause of morbidity and mortality in hospitalized patients worldwide and are one of the most important challenges in intensive care. For example, a recent estimate of sepsis incidence is 240 per 100,000 cases in the United States. The human and economic burden of sepsis is substantial (Grossi et al., 2006, Surg. Infect. (Larchmt) 7:S87-S91). Despite advances in infectious disease and intensive care management and many attempts to develop new treatments, the prevalence of sepsis remains unacceptably high, ranging from 20% to 50%. Identification of symptoms and early and accurate diagnosis of severe blood infections and/or severe sepsis are important for improved treatment and increased survival. Indeed, rapid diagnosis could enhance patient survival by reducing the time interval between taking a blood sample and applying antimicrobial therapy.

For molecular techniques of pathogen detection (eg, PCR and DNA sequencing), proper isolation of the pathogen's DNA is critical to ensure successful detection. Various methods use lysis buffers to improve recovery of pathogen DNA from blood, sometimes involving physical disruption methods such as bead crushing.

The present disclosure takes advantage of the presence of naturally occurring blocking agents in blood and provides a simplified method for isolating pathogen DNA from blood. Blood can be collected from a subject using, for example, commercially available blood collection tubes (eg, BD Vacutainer® blood collection tubes). A number of standard blood collection tubes (some of which contain anticoagulants) are commercially available and are color coded for easy identification, e.g., lavender top tubes with EDTA, sodium citrate. A light blue top tube with hexamethylene chloride, a gray top tube with potassium oxalate and sodium fluoride, and a green top tube with heparin are available. The blood, collected in blood collection tubes containing, for example, EDTA, can be treated with the bead disruption system of the present disclosure (including blocking agents) or conventional bead disruption systems (including blocking agents) without dilution with any buffers or other additives. (without blocking agent). After bead disruption, standard methods, such as those described in Section 4.5, can be used to recover pathogen DNA. Optionally, the recovered pathogen DNA is then analyzed, eg, by methods described in Section 4.6.

Pathogens that cause sepsis are generally bacterial or fungal pathogens. Common bacterial causes of sepsis are Gram-negative bacilli such as E. coli, P. aeruginosa, E. corodens, and H. influenzae. Other bacteria that also cause sepsis are S. Aureus, Streptococcus spp., Enterococcus spp., and Neisseria. Candida spp. are some of the most common fungi that cause sepsis. Accordingly, blood samples can be analyzed for any of the above organisms, either alone or in combination.

7. Examples 7.1 Example 1: A system for bead disruption results in DNA loss.

7.1.1 Materials Materials used in this study are as follows:
Bead crushing tubing: Part #: ARY0007 OPS Diagnostics, 4.5 mL cryovial with 2.0 grams of 100 μm SiO ₂ beads PD Fluid: Peritoneal dialysis containing glucose and balance Na ⁺ , Ca ²⁺ , Mg ²⁺ Liquid BE buffer: Taigen Bioscience, urea containing 1 μg RNA per μl: ACS grade.

7.1.2 Method 2 mL of PD fluid was spiked with EDTA to a concentration of 10 mM; albicans spiked at 5000 CFU/mL was the standard matrix. Twelve different combinations of urea and BE buffer were added to the samples as shown in Table 1 below:

All samples were bead-broken for 45 seconds. After bead disruption, DNA was isolated from the samples using the LabTurbo® 48 Nucleic Acid Extraction System (Taigen Bioscience Corporation, Taipei, Taiwan) using the manufacturer's reagents and protocols. 2.0 ml of DNA isolated from each bead-smashed sample was diluted in 100 μl of TE (Tris-EDTA) buffer. Isolated DNA was subjected to real-time PCR amplification and quantification to determine the amount of target DNA in each sample.

7.1.3 Results The optical density ratio (which is a measure of the purity of the isolated DNA) and the corresponding DNA concentration for each sample are shown in Table 2 below:

The yield of DNA, represented by the intensity of the signal obtained by imaging the signal from the array after PCR amplification and hybridization, is illustrated in FIGS.

7.1.4 Summary In sample 1 containing no blocking agent, C.I. The recovery of albicans DNA was only 5.5 ng/mL. Inclusion of urea as a blocking agent increased recovery by 3-4 fold, and inclusion of RNA as a blocking agent increased recovery by approximately 10-20 fold, with yields reaching a theoretical maximum. This increased recovery is associated with C.I. results in improved PCR gene amplification of albicans.

7.2 Example 2: Extraction of DNA Using the Disclosed Bead Disruption System 7.2.1 Manufacture of the Disclosed Bead Disruption System 250 mg/mL Urea, 25 mg/mL Ethylenediaminetetraacetic Acid (EDTA) tetrasodium salt of, 125 mg/mL adenosine monophosphate, 125 mg/mL guanosine monophosphate, 125 mg/mL cytosine monophosphate, 125 mg/mL thymidine monophosphate, and 75 mg/mL sodium lauroyl sarcosinate A stock solution of blocking agent containing was prepared in TE (Tris/EDTA) buffer.

Two hundred microliters of the stock solution was added to a 4.5-5 mL sample tube and dried by vacuum, resulting in a dried blocking agent deposited on the lower region of the inner wall of the sample tube. Dried blocking agents are expected to be stable for at least one year.

2.0 grams of 100 micron silicon dioxide beads were then added to the sample tube.

7.2.2 Use of the Bead Breaking System of the Present Disclosure 6 mL of urine and 6 mL of peritoneal dialysate were filtered through a 0.4 micrometer sterile filter and then 10,000 colony forming units per milliliter grown in the culture chamber. of Staphylococcus aureus was added to the urine and peritoneal dialysate filtrates.

2.9 mL of spiked urine and 2.9 mL of spiked peritoneal dialysate were placed in a sample tube manufactured as described in Section 7.2.1, or 2.0 grams of 100 micron dioxide Transferred to a sample tube containing silicon beads but no blocking agent.

The tubes were capped, mounted in the MPBio bead beater and run at full power for 30 seconds. The cap was removed and placed in the sample rack of a commercial DNA isolation device. 2 mL of each sample was removed from each tube and then DNA extractant was added (LabTurbo®). DNA extraction was then performed. A 100 microliter DNA extract was obtained from each sample.

それぞれの試料中の抽出されたスタフィロコッカス・アウレウスのＤＮＡの量を、リアルタイムポリメラーゼ連鎖反応によりＧｉｌｌｅｓｐｉｅら，２００５，“Ｓｉｍｕｌｔａｎｅｏｕｓ Ｄｅｔｅｃｔｉｏｎ ｏｆ Ｍａｓｔｉｔｉｓ Ｐａｔｈｏｇｅｎｓ，Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ， Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｕｂｅｒｉｓ，ａｎｄ Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ａｇａｌａｃｔｉａｅ ｂｙ Ｍｕｌｔｉｐｌｅｘ Ｒｅａｌ－Ｔｉｍｅ Polymerase Chain Reaction", J. Am. Dairy Sci. 88:3510-3518. One microliter of each DNA extract was amplified in a 20 microliter reaction.

Samples processed using sample tubes containing no blocking agent had a cycle threshold of 32 for urine and a cycle threshold of 38 for peritoneal dialysate, indicating low DNA recovery.

Samples processed using sample tubes with blocking agent had a cycle threshold of 31 for urine and a cycle threshold of 32 for peritoneal dialysate, and were improved for peritoneal dialysate under these conditions. Recovery was shown.

7.3 Example 3: Blood as Blocking Agent 7.3.1 General This study was conducted to identify the optimal bead crushing conditions for blood samples. Culture-negative blood samples were infected with pathogenic S. cerevisiae. Aureus, E. coli and C. spiked albicans. A positive PCR control was run. This control concentration (genome copies) was defined as theoretical 100% recovery of the introduced pathogen. This study confirmed that it is possible to extract DNA from circulating pathogens using bead disruption in the absence of additives such as buffers, detergents, and the like.

7.3.2 Materials Materials specifically used in the study are as follows:
Bead crushing tube: Item #: ARY0007 OPS Diagnostics, 4.5 mL cryovial with 2.0 grams of 100 μm SiO ₂ beads Blood: Culture negative blood from healthy donors S.E. Aureus, E. coli, and C. albicans cultures: all of ATCC origin.

7.3.3 Methods A series of 38 spiked blood samples were prepared consisting of 3.0 mL blood and 15 μL saline cultures containing cultured pathogens. Nothing was added to each blood sample other than the saline culture containing the cultured pathogen. The disruption tube was processed using a FastPrep® 24 homogenizer (MP Biomedicals) at a speed of 6.5 m/s. DNA was then isolated from the samples using the LabTurbo® 48 Nucleic Acid Extraction System (Taigen Bioscience Corporation) using the manufacturer's reagents and protocols. DNA was amplified by 55 cycles of PCR, hybridized to the array, washed and imaged. The amount of pathogen and the number of bead breaks are shown in Table 3 below:

Genomic output per μl from DNA isolation was calculated for three different pathogens at given spike concentrations. This genome copy value was used as the target for 100% efficiency.

7.3.4 Results The results are illustrated in Figures 8-10 and show the yield of DNA represented by the intensity of the signal obtained by imaging the signal from the array after PCR amplification and hybridization. showing. FIG. 8 shows C.I. Together with the time series of albicans, the 100% target is represented. FIG. 9 shows S.M. Together with the Aureus timeline, the 100% target is represented. FIG. The 100% target is shown along with the time series of stiffness.

7.3.5 Summary There was no evidence of signal loss due to binding of pathogen DNA to the beads for the three different pathogens. At least 100% of the theoretical values were confirmed in all cases. In two cases more than 100% recovery was achieved, presumably due to the presence of DNA from dead bacteria in the spike.

8. Specific Embodiments The present disclosure is illustrated below by specific embodiments.

1. A system for bead disruption comprising a sample tube (i) having an internal cavity accessible by an opening, beads (ii), and a dry blocking agent (iii), said beads and dry blocking agent comprising: A system for bead breaking located within the internal cavity of the sample tube.

2. 2. The system for breaking beads of embodiment 1, wherein the blocking agent comprises one or more chaotropic agents, creatinine, one or more nucleotides, one or more oligonucleotides, or combinations thereof.

3. The blocking agent comprises one or more chaotropic agents, the chaotropic agents being urea, one or more guanidine salts, one or more lithium salts, one or more magnesium salts, one or more surfactants, 3. A system for breaking beads according to embodiment 2, including combinations thereof.

4. 4. The system for breaking beads of embodiment 3, wherein the blocking agent comprises one or more guanidine salts, wherein the guanidine salts comprise guanidine isocyanate, guanidine chloride, or combinations thereof.

5. 5. The system for breaking beads of embodiment 3 or 4, wherein the blocking agent comprises one or more lithium salts, wherein the lithium salts comprise lithium perchlorate, lithium acetate, or combinations thereof.

6. 6. The system for breaking beads of any one of embodiments 3-5, wherein the blocking agent comprises magnesium chloride.

7. wherein said blocking agent comprises one or more surfactants, said surfactants comprising sodium dodecyl sulfate, sodium lauroyl sulfate sarcosinate, polyoxyethylene (20) sorbitan monolaurate, or combinations thereof; A system for breaking beads according to any one of aspects 3-6.

8. Any one of embodiments 2-7, wherein the blocking agent comprises one or more nucleotides, wherein the nucleotides comprise naturally occurring nucleotides, non-naturally occurring nucleotides, or combinations thereof A system for breaking beads according to 1.

9. 9. The system for breaking beads of embodiment 8, wherein the one or more nucleotides comprises one or more naturally occurring deoxyribonucleotides, one or more naturally occurring ribonucleotides, or combinations thereof. .

10. The blocking agent comprises one or more deoxyribonucleotides, wherein the deoxyribonucleotides are deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxycytosine monophosphate, deoxythymidine monophosphate, or combinations thereof. 10. A system for bead breaking according to embodiment 9, comprising:

11. Embodiments wherein said blocking agent comprises one or more ribonucleotides, said ribonucleotides comprising adenosine monophosphate, guanosine monophosphate, cytosine monophosphate, thymidine monophosphate, or combinations thereof. 11. The system for bead crushing according to 9 or 10.

12. Any one of embodiments 2 through 11, wherein said blocking agent comprises one or more oligonucleotides, said oligonucleotides comprising ribonucleotides, deoxyribonucleotides, nucleotide analogs, or combinations thereof. A system for breaking beads according to 1.

13. Said blocking agent comprises one or more oligonucleotides, each of which is independently 2-120 nucleotides long, 2-100 nucleotides long, 2-50 nucleotides long, 2-25 nucleotides long, 5-40 nucleotides long. Embodiments that are nucleotides in length, 2-15 nucleotides in length, 8-120 nucleotides in length, 8-80 nucleotides in length, 10-100 nucleotides in length, 15-50 nucleotides in length, 50-100 nucleotides in length, or 100-120 nucleotides in length 13. A system for bead crushing according to 12.

14. 14. A system for bead disruption according to embodiment 12 or 13, wherein said oligonucleotides comprise DNA and/or RNA.

15. 15. The system for bead breaking according to any one of embodiments 1-14, wherein the internal cavity of the sample tube is at least partially coated with a layer or coating of a blocking agent.

16. 16. A system for breaking beads according to any one of embodiments 1-15, wherein some or all of the beads are partially or completely coated with a layer or coating of blocking agent.

17. 17. The system for bead breaking according to any one of embodiments 1-16, comprising a powder containing said blocking agent.

18. 18. The system for breaking beads of embodiment 17, wherein said powder is a lyophilized powder containing said blocking agent.

19. 19. The system for bead breaking according to any one of embodiments 1-18, wherein the beads are adapted to lyse bacteria, yeast, filamentous fungi, spores, plant cells or animal cells.

20. 20. The system for breaking beads of any one of embodiments 1-19, wherein the beads comprise mineral beads, ceramic beads, glass beads, metal beads, or combinations thereof.

21. Embodiment 20, wherein said beads comprise zirconium beads, zircon beads, zirconia beads, quartz beads, aluminum oxide beads, silicon carbide beads, ceramic beads, silicon dioxide glass beads, stainless steel beads, chromium steel beads, or combinations thereof. A system for bead crushing as described in .

22. 22. A system for breaking beads according to any one of embodiments 1-21, wherein the beads have a diameter in the range of 50 μm to 3 mm.

23. 23. The system for bead breaking according to any one of embodiments 1-22, further comprising ethylenediaminetetraacetic acid (EDTA) and/or its sodium salt located within the internal cavity of the sample tube.

24. 23. The system for bead breaking according to any one of embodiments 1-22, further comprising creatinine located within the internal cavity of the sample tube.

25. 25. A method of lysing cells contained in a liquid sample (e.g., for extracting nucleic acids from the cells), wherein the liquid sample is subjected to bead disruption according to any one of embodiments 1-24. A method comprising agitating under conditions sufficient to lyse cells in a sample tube of the system.

26. A method for lysing cells (e.g., for extracting nucleic acids from the cells) contained in a liquid sample containing an exogenous blocking agent, wherein the liquid sample is lysed in a system for bead disruption comprising a sample tube and beads in the absence of lysis buffer and/or additives.

27. A method of lysing (e.g., for extracting nucleic acids from) cells contained in a liquid sample that has not been incubated with a lysis buffer, wherein the liquid sample and one or more blocking agents are combined with the sample. optionally, the one or more blocking agents are present in the sample tube of any one of embodiments 1-24, comprising agitation in a system for bead disruption comprising a tube and beads; Method.

28. 28. The method of embodiment 27, wherein said liquid sample comprises an endogenous blocking agent.

29. 29. The method of any one of embodiments 26-28, wherein the beads are adapted to lyse bacteria, yeast, filamentous fungi, spores, plant cells, or animal cells.

30. 30. The method of any one of embodiments 26-29, wherein the beads comprise mineral beads, ceramic beads, glass beads, metal beads, or combinations thereof.

31. 30. The beads comprise zirconium beads, zircon beads, zirconia beads, quartz beads, aluminum oxide beads, silicon carbide beads, ceramic beads, silicon dioxide glass beads, stainless steel beads, chromium steel beads, or combinations thereof, Embodiment 30 The method described in .

32. 32. The method of any one of embodiments 26-31, wherein said beads have a diameter in the range of 50 μm to 3 mm.

33. 33. The method of any one of embodiments 25-32, further comprising placing the liquid sample in the sample tube prior to agitating the liquid sample.

34. 34. The method of any one of embodiments 25-33, wherein said agitating comprises subjecting said bead breaking system to a vibratory motion.

35. 35. The method of any one of embodiments 25-34, wherein the sample is a biological sample, an environmental sample, or a food product.

36. The sample may be blood, serum, saliva, urine, gastric juice, digestive juice, tear fluid, feces, semen, vaginal fluid, interstitial fluid, fluid from tumor tissue, ocular fluid, sweat, mucus, cerumen, oil, glandular secretions. material, breath, cerebrospinal fluid, hair, nails, skin cells, plasma, fluids obtained from nasal swabs, fluids obtained from nasopharyngeal lavage, cerebrospinal fluid, tissue samples, fluids or tissues obtained from throat swabs, Fluid or tissue obtained from wound swabs, biopsy tissue, placental fluid, amniotic fluid, peritoneal dialysate, umbilical cord blood, lymphatic fluid, body cavity fluid, sputum, pus, microflora, meconium, milk, or any of the foregoing; 36. The method of embodiment 35, which is a biological sample selected from extracted or fractionated samples.

37. 37. The method of embodiment 36, wherein the biological sample is urine, sputum, or a sample processed, extracted or fractionated from urine.

38. 37. The method of embodiment 36, wherein the biological sample is sputum or a sample processed, extracted or fractionated from sputum.

39. 37. The method of embodiment 36, wherein the biological sample is a wound swab or a sample processed, extracted or fractionated from a wound swab.

40. 37. The method of embodiment 36, wherein the biological sample is blood or a sample processed, extracted or fractionated from blood.

41. 41. The method of embodiment 40, wherein said blood comprises an anticoagulant.

42. 42. The method of embodiment 41, wherein the anticoagulant is EDTA.

43. 42. The method of embodiment 41, wherein the anticoagulant is a citrate (eg, sodium citrate).

44. 42. The method of embodiment 41, wherein the anticoagulant is an oxalate (eg, potassium oxalate).

45. 42. The method of embodiment 41, wherein the anticoagulant is heparin (eg, sodium heparin).

46. Embodiment 41 further comprising transferring the blood from the blood collection tube to the sample tube prior to agitation, wherein optionally all or only a portion of the blood in the blood collection tube is transferred to the sample tube. The method described in .

47. 47. The method of embodiment 46, wherein the blood collection tube contains an anticoagulant.

48. 48. The method of embodiment 47, wherein the anticoagulant is EDTA.

49. 48. The method of embodiment 47, wherein said anticoagulant is a citrate (eg, sodium citrate).

50. 48. The method of embodiment 47, wherein said anticoagulant is an oxalate (eg, potassium oxalate).

51. 48. The method of embodiment 47, wherein the anticoagulant is heparin (eg, sodium heparin).

52. 52. The method of any one of embodiments 46-51, further comprising collecting blood in a blood collection tube prior to transferring the blood to the sample tube.

53. 53. The method of embodiment 52, wherein said blood collection tube contains an anticoagulant prior to said collection.

54. 54. The method of embodiment 52 or 53, further comprising transferring and/or storing the blood in the blood collection tube prior to transferring the blood to the sample tube.

55. A method of lysing cells contained in a blood sample (e.g., for extracting nucleic acids from cells) without incubation with a lysis buffer comprising: (a) combining beads and blood in a blood-containing blood collection tube; and (b) lysing cells contained in the blood sample by agitating the blood in the presence of the beads.

56. 56. The method of embodiment 55, wherein the beads are added to a blood collection tube containing blood.

57. 56. The method of embodiment 55, wherein the blood is collected in a blood collection tube containing beads.

58. 58. The method of any one of embodiments 55-57, wherein the blood collection tube comprises an anticoagulant.

59. 59. The method of embodiment 58, wherein said anticoagulant is EDTA.

60. 59. The method of embodiment 58, wherein said anticoagulant is a citrate (eg, sodium citrate).

61. 59. The method of embodiment 58, wherein said anticoagulant is an oxalate (eg, potassium oxalate).

62. 59. The method of embodiment 58, wherein said anticoagulant is heparin (eg, sodium heparin).

63. 37. The method of embodiment 36, wherein the biological sample is peritoneal dialysate or a sample processed, extracted or fractionated from peritoneal dialysate.

64. 36. The method of embodiment 35, wherein the sample is soil, groundwater, surface water, wastewater, or a sample processed, extracted or fractionated from any of the foregoing.

65. 65. The method of any one of embodiments 25-64, wherein said cells comprise one or more pathogens.

66. 66. The method of embodiment 65, wherein said one or more pathogens comprises one or more bacterial pathogens, viral pathogens, fungal pathogens, or combinations thereof.

67. The one or more pathogens are Mycobacterium tuberculosis, Mycobacterium avium subsp. paratuberculosis, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes, Streptococcus pneumoniae , Streptococcus agalactia, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter spp., Bordetella pertussis, Neisseria meningitidis, Bacillus anthracis, Nocardia spp. species, Actinomyces spp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp., Pneumocystis jirovecii, Influenza A virus, Cytomegalovirus, Rhinovirus, Enterococcus faecium, Acinetobacter baumannii, Corynebacterium spp. 67. The method of embodiment 65 or 66, comprising one or more of Amycolatum, Enterobacter aerogenes, Enterococcus faecalis CI4413, Serratia marcescens, Streptococcus equi and Candida albicans.

68. The sample is sputum or a sample processed, extracted or fractionated from sputum, and the one or more pathogens are Mycobacterium tuberculosis, Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA ), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter spp., Bordetella pertussis, Neisseria Meningitidis, Bacillus anthracis, Nocardia spp., Actinomyces spp., Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp., Pneumocystis jirovecii, influenza A virus, cytomegalovirus, and one of the rhinoviruses 66. The method of embodiment 65, comprising the above.

69. 69. The method of embodiment 68, wherein said one or more pathogens comprises Mycobacterium tuberculosis.

70. The sample is milk or semen, or a sample processed, extracted or fractionated from milk, soil, faeces or semen, and the one or more pathogens comprise Mycobacterium avium subsp. paratuberculosis. , embodiment 65.

71. The sample is a wound swab, or a sample processed, extracted or fractionated from a wound swab, and the one or more pathogens are E. coli. Cori, P. Aeruginosa, E. Faecium, S. Aureus, K. Newmonier, A. Baumannii, C. Amicolatum, E. Aerogenes, E. Faecalis CI4413, S. Marcescens, S. Equi, and C.I. 66. The method of embodiment 65, comprising one or more of Albicans.

72. The sample is peritoneal dialysate, or a sample that has been processed, extracted or fractionated from peritoneal dialysate, and the one or more pathogens are S. cerevisiae. aureus and/or P. 66. The method of embodiment 65, comprising Aeruginosa.

73. 73. The method of any one of embodiments 25-72, wherein said liquid sample comprises cells from multiple species.

74. 74. The method of any one of embodiments 25-73, further comprising withdrawing the liquid sample from the sample tube after cell lysis.

75. 75. The method of embodiment 74, further comprising purifying said nucleic acid from said collected liquid sample.

76. 76. The method of any one of embodiments 25-75, further comprising analyzing one or more of said nucleic acids.

77. 77. The method of embodiment 76, wherein said analysis is performed using a microarray or by sequencing said one or more nucleic acids.

78. 78. The method of embodiment 76 or 77, wherein the target sequence is amplified prior to performing said analysis.

79. 79. The method of embodiment 78, wherein said target sequence is amplified by PCR.

80. 80. The method of any one of embodiments 25-79, wherein said nucleic acid comprises DNA.

81. 81. The method of any one of embodiments 25-80, wherein said nucleic acid comprises RNA.

82. A kit for lysing cells contained in a liquid sample (e.g., for extracting nucleic acids from the cells), the system for bead disruption according to any one of embodiments 1 to 24, and optionally (i) one or more components for preparing a liquid sample; (ii) one or more oligonucleotides for amplifying one or more of said nucleic acids; (iii) detecting one or more of said nucleic acids. or (iv) any combination of (i)-(iii).

83. one or more components for preparing the liquid sample, and wherein the one or more components for preparing the liquid sample include water, saline, buffers, filters, or combinations thereof , embodiment 82.

84. 84. The kit of embodiment 82 or 83, comprising one or more oligonucleotides for amplifying one or more of said nucleic acids.

85. 85. The kit of any one of embodiments 82-84, comprising one or more probes for detecting one or more of said nucleic acids.

86. Kit for obtaining a system for bead disruption according to any one of embodiments 1 to 24, comprising sample tubes, beads and dried blocking reagent.

87. 87. The kit of embodiment 86, wherein said beads and/or dried blocking reagent are included in the kit separately from sample tubes.

88. 87. The kit of embodiment 86, wherein the beads and/or dried blocking reagent are contained in the kit within a sample tube.

89. one or more components for preparing a sample containing cells for nucleic acid extraction using the bead disruption system; one or more oligonucleotides for amplifying one or more nucleic acids; 89. The kit of any one of embodiments 86-88, further comprising one or more probes for detecting the above nucleic acids, or combinations thereof.

90. A system (1) for bead breaking comprising: a container member (2) having an internal cavity (3); comprising an opening (4) and a closure (6) for closing said opening (4), a plurality of macroscopic mineral particles (7) being arranged in said internal cavity (3), said Particles (7) are contained in the sample fluid (5) when the sample fluid (5) is filled in the internal cavity (3) and the bead breaking system (1) is subjected to mechanical vibration. urea and/or at least one guanidine salt and/or at least one surfactant in a system (1) for bead disruption comprising a sample tube adapted to mechanically disrupt the cell walls of microorganisms in A system (1) for breaking beads, characterized in that a blocking agent (8) comprising is placed in a dried form in the internal cavity (3) of said sample tube.

91. Embodiments wherein said blocking agent (8) comprises deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxycytosine monophosphate, deoxythymidine monophosphate, or a mixture of at least two of these monophosphates. 90. A system (1) for bead crushing.

92. 92. According to embodiment 90 or 91, wherein said blocking agent (8) comprises adenosine monophosphate, guanosine monophosphate, cytosine monophosphate, thymidine monophosphate, or a mixture of at least two of these monophosphates. A system for breaking beads as described (1).

93. 93. The method of embodiment 90 to 92, wherein said at least one monophosphate contained in said blocking agent (8) is an oligonucleotide of at least 2 to at most 120 nucleotides. A system (1) for breaking beads according to any one of the preceding claims.

94. 94. Any of embodiments 90-93, wherein the at least one surfactant comprises sodium dodecyl sulfate, sodium lauroyl sulfate sarcosinate, and/or polyoxyethylene (20) sorbitan monolaurate. 1. A system (1) for breaking beads according to one.

95. 95. Any one of embodiments 90 to 94, wherein said dried blocking agent is loosely disposed in the internal cavity (3) of said container member (2), preferably in powdered form. 1. A system (1) for bead breaking according to claim 1.

96. 96. System for breaking beads according to any one of embodiments 90-95, characterized in that the inner wall of said container member (2) is at least partially coated with a layer or coating of a blocking agent ( 1).

97. 97. Bead crushing according to any one of embodiments 90-96, characterized in that ethylenediaminetetraacetic acid (EDTA) and/or its sodium salt is placed in the inner cavity (3) of the sample tube. system (1).

98. 98. System (1) for breaking beads according to any one of embodiments 90-97, characterized in that creatinine is placed in the internal cavity (3) of the sample tube.

99. Use of the system (1) for bead disruption according to any one of embodiments 90 to 98 for the extraction of deoxyribonucleic acid and/or ribonucleic acid from microorganisms.

100. A method for extracting deoxyribonucleic acid and/or ribonucleic acid from a microorganism comprising providing a sample fluid (5) presumed to contain said microorganism and a plurality of mineral particles (7) movable relative to each other. is introduced into the sample fluid (5), and the sample fluid (5) containing the particles (7) is subjected to a mechanical mechanical In said method, a blocking agent (8) comprising urea and/or at least one guanidine salt and/or at least one surfactant is added to said sample fluid (5 ), wherein said particles (7) are introduced before and/or during agitation.

101. The amount of urea is such that the concentration of urea dissolved in said sample fluid (5) is between 10 and 100 grams/liter, especially between 20 and 50 grams/liter, preferably 25 grams/liter. 101. A method according to embodiment 100, characterized in that it is combined with the amount of said sample fluid (5) to be in the range between grams/liter and 35 grams/liter.

102. Before and/or during said particles (7) are vibrated, at least one of the following monophosphates: deoxyadenosine monophosphate, deoxyguanosine monophosphate, deoxycytosine monophosphate, deoxythymidine monophosphate 102. Method according to embodiment 100 or 101, characterized in that one species is introduced into said sample fluid (5).

103. Before and/or while said particles (7) are vibrated, at least one of the following monophosphates: adenosine monophosphate, guanosine monophosphate, cytosine monophosphate, thymidine monophosphate 103. A method according to any one of embodiments 100 to 102, characterized in that it is introduced into the sample fluid (5).

104. characterized in that creatinine and/or ethylenediaminetetraacetic acid (EDTA) and/or sodium salts thereof are introduced into the sample fluid (5) before and/or while the particles (7) are vibrated. 104. The method of any one of embodiments 100-103, wherein:

9. INCORPORATION BY REFERENCE All publications, patents, patent applications, and other references cited in this application are referenced by each individual publication, patent, patent application, or other reference for all purposes. To the same extent as individually indicated to be incorporated by reference, they are incorporated by reference in their entirety for all purposes. In the event of a conflict between the teachings of one or more of the incorporated references and the present disclosure, the teachings of this specification are intended.

1 system for bead breaking, 2 sample tube, 3 internal cavity, 4 opening, 5 sample fluid, 6 closure, 7 beads, 8 blocking agent

Claims (33)

1. A method of lysing cells contained in blood, comprising: in the absence of a lysis buffer, in a system for bead disruption comprising (i) a sample tube or blood collection tube and (ii) beads. A method comprising agitating a treated, extracted or fractionated sample. 2. The method of claim 1, wherein said beads are adapted to lyse bacteria, yeast, filamentous fungi, spores, plant cells or animal cells. 3. The method of claim 1 or 2, wherein the beads comprise mineral beads, ceramic beads, glass beads, metal beads, or combinations thereof. 11. The beads comprise zirconium beads, zircon beads, zirconia beads, quartz beads, aluminum oxide beads, silicon carbide beads, ceramic beads, silicon dioxide glass beads, stainless steel beads, chromium steel beads, or combinations thereof. Or the method of 2. A method according to any one of claims 1 to 4, wherein said beads have a diameter in the range from 50 µm to 3 mm. 6. The method of any one of claims 1-5, further comprising collecting blood in a blood collection tube. 7. The method of any one of claims 1-6, further comprising placing blood, or a sample treated, extracted or fractionated therefrom, in a sample tube prior to agitation. 8. A method according to any one of claims 1 to 7, wherein said agitating comprises subjecting said bead breaking system to an oscillating motion. 9. The method of any one of claims 1-8, wherein the blood comprises an anticoagulant. 10. The method of claim 9, wherein the anticoagulant is EDTA. 10. The method of claim 9, wherein the anticoagulant is a citrate (eg sodium citrate). 10. The method of claim 9, wherein the anticoagulant is an oxalate (eg, potassium oxalate). 10. The method of claim 9, wherein the anticoagulant is heparin. 14. A method according to any one of claims 1 to 13, wherein the blood is agitated. 14. A method according to any one of claims 1 to 13, wherein the sample processed, extracted or fractionated from blood is agitated. 16. The method of any one of claims 1-15, wherein the system for bead breaking comprises a sample tube and beads. 16. The method of any one of claims 1-15, wherein the bead breaking system comprises a blood collection tube and beads. 18. The method of any one of claims 1-17, wherein the cells comprise one or more pathogens. 19. The method of any one of claims 1-18, wherein the blood comprises cells from multiple species. 20. The method of any one of claims 1-19, further comprising recovering the lysate from the sample tube after cell lysis. 21. The method of claim 20, further comprising purifying nucleic acids from said lysate. further comprising analyzing said nucleic acid, optionally
a) said analysis is performed using a microarray or by sequencing said one or more nucleic acids;
22. The method of claim 21, b) optionally amplifying the target sequence by PCR prior to performing said analysis. 23. The method of claim 21 or 22, wherein said nucleic acid comprises DNA and/or RNA. A kit for lysing cells present in a blood sample, comprising a blood collection tube and beads suitable for bead disruption. 25. The kit of Claim 24, wherein the blood collection tube contains an anticoagulant. 26. The kit of claim 25, wherein said anticoagulant is EDTA. 26. The kit of claim 25, wherein said anticoagulant is citrate. 26. The kit of claim 25, wherein said anticoagulant is oxalate. 26. The kit of claim 25, wherein said anticoagulant is heparin. 30. The kit of any one of claims 24-29, wherein the beads are packaged separately from the blood collection tube. 31. A method of lysing cells contained in blood, comprising combining blood with beads and a blood collection tube in the kit of claim 30, and lysing the tubes until the cells contained in the blood are lysed. agitating. 30. The kit of any one of claims 24-29, wherein the beads are packaged in blood collection tubes. 33. A method of lysing cells contained in blood, comprising combining blood with beads and a blood collection tube in the kit of claim 32, and lysing the tubes until the cells contained in the blood are lysed. agitating.

Images